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Lee and colleagues of the National Bone Health Alliance
(NBHA) call for expanded fracture liaison services (FLS),
because secondary prevention represents the most productive
opportunity for pharmacotherapy. Intuitively this seems logical,
but supporting arguments do not stand up to scrutiny.1 2
The effectiveness of FLS should be tested in randomised
controlled trials (RCTs) to see whether this approach can achieve
the “quality outcomes” referred to1—prevention of second
fractures—as opposed to the proportion of patients evaluated
or prescribed drugs. Presently, evidence on FLS is limited to
observational studies or invalid modelling based cost
effectiveness extrapolations.3
Lee and colleagues cite HORIZON—the only secondary
prevention trial of patients after a hip fracture—as proof that
FLS are effective.4 However, after median follow-up of nearly
two years, secondary hip fracture rates did not differ
significantly with zoledronic acid versus placebo (2.0% v 3.5%).
There were fewer clinical non-vertebral fractures (7.6% v 10.7%;
absolute risk reduction 3.1%; relative risk reduction 27%;
P=0.03) and fewer clinical vertebral fractures (1.7% v 3.8%;
2.1%; 55%; P=0.02). But even under “artificial” circumstances
for assessing effectiveness,3 5 patients did not benefit from
pharmacotherapy. Fundamental flaws including early
termination, selective outcome reporting, and loss to follow-up
undermineHORIZON’s generalisability.Moreover, participants’
mean age was only 74 years, whereas the mean age of patients
with hip fracture is about 80 years in Europe, and more than
three in four hip fractures occur in people over 75.
We share NBHA’s desire to prevent clinically important
fractures. Nonetheless, we must abstain from interventions (a)
that are not proved effective, (b) for which the ratio of potential
benefit to potential harm is poor, or (c) for which cost prohibits
the development of more effective alternative strategies. Pending
demonstration of the utility of FLS in a valid RCT, we
recommend discretion in advocating and implementing this
concept.
Vigorous discussion of current scientific evidence on how best
to reduce fracture burden is important. Orthodoxy, inattention
to methodological problems in RCTs, and lack of transparency
concerning competing interests remain barriers to achieving the
best and most cost effective care for our patients.6
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